A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia.
OBJECTIVE
The objective of this study was to assess the efficiency of topical applications of podophyllin resin (25%) (P) versus podophyllin resin (25%) together with acyclovir cream (5%) (PA) in the treatment of oral hairy leukoplakia (OHL) in accordance with the following criteria: (1) number of applications necessary for the total clinical resolution of OHL; (2) correlation between the decrease of lesion size and the number of applications; (3) total clinical resolution of OHL; and (4) clinical reevaluation 12 months after the end of treatment.


METHODS
Forty-six OHLs were treated with P (P group) or with PA (PA group). Applications were performed weekly. Student t, Fisher exact, and Pearson correlation tests were used for statistical analysis.


RESULTS
All 24 lesions from the PA group presented total clinical resolution while 4 lesions from the P group did not. The P group required up to 25 applications performed weekly while the PA group required up to 18. Observed was a negative significant association between the size of the lesions and the number of applications performed weekly in the PA group.


CONCLUSIONS
The present study demonstrated the following: (1) P and PA topical treatments presented a similar average number of applications performed weekly; (2) both groups showed the same clinical response at 12 months post-therapy; and (3) PA presented a 100% clinical resolution and a continuous decrease in OHL size over the course of weekly applications.
Moura
Mariela Dutra Gontijo
MD
Oral Surgery, Medicine and Pathology Department, School of Dentistry, Federal University of Minas Gerais and Orestes Diniz's Treatment Center of Parasitic and Infectious Diseases, Minas Gerais, Brazil.
Guimarães
Tatiane Roberta Morais
TR
Fonseca
Linaena Méricy Silva
LM
de Almeida Pordeus
Isabela
I
Mesquita
Ricardo Alves
RA
D000212:Acyclovir / Q000008:administration & dosage*; D000287:Administration, Topical; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage*; D017733:Leukoplakia, Hairy / Q000188:drug therapy*; D008875:Middle Aged; D011033:Podophyllin / Q000008:administration & dosage*
D000998:Antiviral Agents; D007641:Keratolytic Agents; D011033:Podophyllin; D000212:Acyclovir